Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

33%

5 trials in Phase 3/4

Results Transparency

92%

12 of 13 completed trials have results

Key Signals

12 with results

Enrollment Performance

Analytics

Phase 2

7(50.0%)

Phase 4

3(21.4%)

Phase 3

2(14.3%)

Phase 1

2(14.3%)

14Total

Phase 2(7)

Phase 4(3)

Phase 3(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05918406Phase 4Completed

Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya

Role: lead

NCT06329687Phase 4Terminated

A Study Evaluating the Safety of the Nasal Pump

Role: lead

NCT05700422Phase 4Completed

Nasal Spray Study in Sjogren's Dry Eye Disease

Role: collaborator

NCT04957758Phase 2Completed

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

Role: lead

NCT03920215Phase 2Completed

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Role: lead

NCT05576415Phase 1Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease

Role: collaborator

NCT05378945Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Role: collaborator

NCT05566717Unknown

An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity

Role: collaborator

NCT03873246Phase 2Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Role: lead

NCT04072146Phase 1Completed

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

Role: lead

NCT03633461Phase 2Completed

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

Role: lead

NCT03688802Phase 2Completed

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

Role: lead

NCT03452397Phase 2Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Role: lead

NCT04036292Phase 3Completed

Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Role: lead

NCT03636061Phase 2Completed

Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Role: lead

All 15 trials loaded